Evaluation of the Association between COVID-19 Vaccines and Pulmonary Embolism

dc.authorid0009-0000-9743-5462
dc.contributor.authorDogan, Coskun
dc.contributor.authorSamanci, Samet
dc.date.accessioned2025-05-10T19:58:45Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractIntroduction: This study investigated the clinical and radiological characteristics and demographics of patients who developed pulmonary embolism (PE) after Coronavirus disease-2019 (COVID-19) vaccination. Methods: The cases of PE were analyzed retrospectively. Data on clinical, demographic, and radiologic characteristics, laboratory findings, Pulmonary Embolism Severity Index (PESI) scores, early mortality scores, PE severity classes, and risk categories for early mortality (low-risk, intermediate-high-risk, intermediate-low-risk and high-risk) were collected from patient files as defined in the European Society of Cardiology guidelines. Patients were divided into two groups: those who had received a COVID-19 vaccine (group 1) and those who had not (group 2). Patients who developed PE within 1 month after vaccination were analyzed separately. Results: A total of 97 patients were included in the study, of whom 61 (62.9%) patients were female. Seventy-five (77.3%) study patients with PE had a history of COVID-19 vaccination (group 1), and 22 (22.7%) had never been vaccinated (group 2). Five (6.6%) patients had received a vaccine within 1 month before PE developed. No significant differences were found between groups 1 and 2 regarding demographics, clinical and radiologic characteristics, laboratory findings, PESI scores, early mortality scores, and PE severity classes (p>0.05), except for mean pulmonary artery pressures. The mean age of patients who developed PE within 1 month after vaccination was 74.6 years, and 80% of these patients were female. The average time to PE after vaccination was 22.2 days, and the mean PESI score was 86.6. Two patients (40%) were in the low-risk category for early mortality and one patient (20%) was in the intermediate/high-risk category. Conclusion: Overall, the characteristics of patients who developed PE after COVID-19 vaccination were comparable to those of patients who had not received a vaccine injection. No statistically significant increases in the incidence of PE were observed within the first month after being vaccinated.
dc.identifier.doi10.4274/imj.galenos.2024.56798
dc.identifier.endpage206
dc.identifier.issn2619-9793
dc.identifier.issn2148-094X
dc.identifier.issue3
dc.identifier.scopusqualityN/A
dc.identifier.startpage199
dc.identifier.trdizinid1280619
dc.identifier.urihttps://doi.org/10.4274/imj.galenos.2024.56798
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1280619
dc.identifier.urihttps://hdl.handle.net/20.500.14730/13629
dc.identifier.volume25
dc.identifier.wosWOS:001296714900005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofIstanbul Medical Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectCOVID-19
dc.subjectCOVID-19 vaccine
dc.subjectpulmonary embolism
dc.titleEvaluation of the Association between COVID-19 Vaccines and Pulmonary Embolism
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
13629.pdf
Boyut:
599.15 KB
Biçim:
Adobe Portable Document Format